Flavonoids of St. John’s Wort Reduce HPA Axis Function in the Rat

Abstract

A common biological alteration in patients with major depression is the activation of the hypothalamic-pituitary-adrenal (HPA) axis, manifested as hypersecretion of adrenocorticotropic hormone (ACTH) and cortisol. The hyperactivity of the HPA axis in depressed patients can be corrected during clinically effective therapy with standard antidepressant drugs such as imipramine, indicating that the HPA axis may be an important target for antidepressant action. We previously showed that a methanolic extract of St. John’s wort (SJW) and hypericin, one of its active constituents, both have delayed effects on the expression of genes that are involved in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis [1], whereas the phloroglucinol derivative hyperforin was inactive in the same model [2]. Since flavonoids of SJW are also discussed as active constituents it was of interest to determine whether these compounds can modulate HPA axis function. Imipramine (15 mg/kg), hypericin (0.2 mg/kg), hyperoside (0.6 mg/kg), isoquercitrin (0.6 mg/kg) and miquelianin (0.6 mg/kg) given daily by gavage for two weeks significantly down-regulated circulating plasma levels of ACTH and corticosterone by 40 - 70 %. However, none of the compounds tested had an effect on plasma ACTH and corticosterone levels after chronic treatment (daily gavage for 8 weeks). Our data suggest that besides hypericin, flavonoids of SJW play an important role in the modulation of HPA axis function. Furthermore, the results support the hypothesis that flavonoids are involved in the antidepressant effects of SJW.

References

• 1 Butterweck V, Winterhoff H, Herkenham M. St. John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats.  Mol Psychiatry. 2001;  6 547-64
• 2 Butterweck V, Winterhoff H, Herkenham M. Hyperforin-containing extracts of St. John's wort fail to alter gene transcription in brain areas involved in HPA axis control in a long-term treatment regimen in rats.  Neuropsychopharmacol. 2003;  28 2160-8
• 3 Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression.  Int Clin Psychopharmacol. 2000;  5 61-8
• 4 Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial.  Brit Med J. 2000;  321 536-9
• 5 Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L.  Pharmacopsychiatry. 1997;  30 129-34
• 6 Butterweck V. Mechanism of action of St.  John's wort in depression: What is known? CNS Drugs. 2003;  17 539-62
• 7 Müller W E, Singer A, Wonnemann M, Hafner U, Rolli M, Schäfer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract.  Pharmacopsychiatry. 1998;  31 16-21
• 8 Butterweck V, Petereit F, Winterhoff H, Nahrstedt A. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test.  Planta Med. 1998;  64 291-4
• 9 Butterweck V, Jürgenliemk G, Nahrstedt A, Winterhoff H. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test.  Planta Med. 2000;  66 3-6
• 10 Noeldner M, Schotz K. Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swimming test.  Planta Med. 2002;  68 577-80
• 11 Gold P W, Licinio J, Wong M L, Chrousos G P. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs.  Ann NY Acad Sci. 1995;  771 716-29
• 12 Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation.  Endocr Rev. 1996;  17 187-205
• 13 Barden N, Reul J M, Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?.  Trends Neurosci. 1995;  18 6-11
• 14 Brady L S, Whitfield H, Jr, Fox R J, Gold P W, Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications.  J Clin Invest. 1991;  87 831-7
• 15 Brady L S, Gold P W, Herkenham M, Lynn A B, Whitfield H J. The antidepressant fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications.  Brain Res. 1992;  572 117-25
• 16 Frost P, Bornstein S, Ehrhart-Bornstein M, O’Kirwan F, Hutson C, Heber D, Go V, Licinio J, Wong M L. The prototypic antidepressant drug, imipramine, but not Hypericum perforatum (St. John's Wort), reduces HPA-axis function in the rat.  Horm Metab Res. 2003;  35 602-6
• 17 Armario A, Garcia-Marquez C. Tricyclic antidepressants activate the pituitary-adrenal axis in the rat. Tolerance to repeated drug administration.  Eur J Pharmacol. 1987;  140 239-44
• 18 Kitamura Y, Araki H, Gomita Y. Influence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test.  Pharmacol Biochem Behav. 2002;  71 63-9
• 19 Rigal J, Albin H, Fanca X, Demotes-Mainard F, Vincon G. The influence of the route of administration of imipramine on imipramine and desipramine blood levels.  J Clin Psychopharmacol. 1989;  9 364-7
• 20 Juergenliemk G, Boje K, Huewel S, Lohmann C, Galla H J, Nahrstedt A. In vitro studies indicate that miquelianin (quercetin 3-O-beta-glucuronopyranoside) is able to reach the CNS from the small intestine.  Planta Med. 2003;  69 1013-7